6,218 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Purchased by Integrated Advisors Network LLC

Integrated Advisors Network LLC purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,218 shares of the company’s stock, valued at approximately $294,000.

A number of other hedge funds also recently bought and sold shares of KYMR. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock worth $101,778,000 after purchasing an additional 72,351 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Kymera Therapeutics by 4.7% in the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after purchasing an additional 547 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 6.7% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,471 shares of the company’s stock worth $984,000 after purchasing an additional 1,531 shares in the last quarter. FORA Capital LLC bought a new position in Kymera Therapeutics in the 1st quarter worth about $818,000. Finally, Jennison Associates LLC bought a new position in Kymera Therapeutics in the 1st quarter worth about $17,122,000.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Up 0.6 %

NASDAQ KYMR opened at $46.47 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $53.27. The firm has a market capitalization of $2.87 billion, a P/E ratio of -19.20 and a beta of 2.21. The company has a 50-day moving average price of $47.04 and a 200-day moving average price of $40.65.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.90) EPS. As a group, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.85 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on KYMR. B. Riley boosted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Oppenheimer boosted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Morgan Stanley boosted their target price on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 14th. Wells Fargo & Company boosted their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Guggenheim boosted their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $49.15.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.